Shares in consumer healthcare firm Haleon sink amid weak demand for cold and flu medicine

The FTSE 100 company said revenues rose 2.5% to £2.87bn in the three months to September 30, and it is on track for sales growth of around 2.5% in 2026.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.thisismoney.co.uk)